-
July 26, 2021 Akome Biotech Patents Psychedelic Drug Formulation to Treat Parkinson’s DiseaseThere is currently no known cure for the disease affecting 10 million people worldwide, but...
-
July 23, 2021 How a Psilocybin Study on AIDS Survivors Could Solve a Big Problem with Psychedelic TherapyA group psilocybin study paves the way for increased scalability of novel treatments that typically...
-
July 23, 2021 Psychedelic Business Spotlight: July 23, 2021This week in psychedelic business news: Psychedelics as a treatment for obesity and TBIs, plus...
-
July 22, 2021 Cybin Receives Conditional Approval to Trade on NYSE AmericanAnd in other psychedelic stock news, Origin Therapeutics launches to make equity investments in emerging...
-
July 21, 2021 Megan Pormer Calls Ketamine ‘One of the Most Incredible Experiences of My Life’ While Talking Psychedelics with Lamar OdomThe Iranian model, actress and scientist bonds with former NBA star over spiritual experiences with...
-
July 21, 2021 Wake Network Partners with Lieber Institute to Develop Genetics-Based Screening System for Psychedelic TherapiesFungi bioscience company describes the project as “one of the most robust genetics research initiatives...
-
July 20, 2021 Free Ketamine Treatment Now Available for Canadian VeteransMedavie Blue Cross partners with medical research company Braxia Scientific to cover ketamine care for...
-
July 19, 2021 Levitee Labs to Begin Trading on the CSE This WeekThe emerging wellness company aims to transform mental health and addiction treatments through the integration...
-
July 19, 2021 Third Psychedelic Stock ETF Coming Soon, Core One Labs Prepares to List on NASDAQAdvisorshares Plant Medicine ETF will be listed on the NYSE Arca under the symbol PSIL.
-
July 16, 2021 How Wesana Health CEO Daniel Carcillo Plans to Protect Athletes From Traumatic Brain InjuryAnd why the two-time Stanley Cup champion does not imagine working with the NHL in...
